NCT03908008View on ClinicalTrials.gov

Efficacy and Safety Study of MT10107 in the Treatment of Glabella Line

PHASE3CompletedINTERVENTIONAL
Enrollment

136

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

May 31, 2014

Study Completion Date

September 30, 2014

Conditions
Glabellar Frown Lines
Interventions
DRUG

Botox (Botulinum toxin type A)

20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.

DRUG

MT10107 (Botulinum toxin type A)

20U of the investigational drug will be intramuscularly injected to 5 sites of the glabella line. Treatment will be conducted just once in visit 2.

All Listed Sponsors
lead

Medy-Tox

INDUSTRY

NCT03908008 - Efficacy and Safety Study of MT10107 in the Treatment of Glabella Line | Biotech Hunter | Biotech Hunter